POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the principal intracellular cation; it corrects hypokalemia and maintains cellular membrane potential. Sodium chloride provides sodium and chloride ions to maintain fluid balance and osmolarity.
| Metabolism | Potassium is primarily eliminated by the kidneys; not metabolized. Sodium chloride is distributed and excreted unchanged. |
| Excretion | Renal: >90% of administered potassium is excreted by the kidneys, primarily via distal tubular secretion in the collecting duct. Fecal: <10% eliminated in feces. Biliary: negligible. |
| Half-life | Not applicable as potassium is an electrolyte; its serum half-life depends on redistribution and renal function. In normal renal function, excess exogenous potassium is eliminated within hours; terminal elimination half-life is approximately 2-4 hours in healthy individuals but prolonged in renal impairment. |
| Protein binding | Not significantly bound to plasma proteins; essentially 0% bound. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg total body water; distributes throughout extracellular and intracellular compartments. Clinical meaning: rapid distribution into the intracellular space; Vd approximates total body water. |
| Bioavailability | Intravenous: 100% (directly into bloodstream). Oral: 90-100% (well absorbed from the gastrointestinal tract, primarily in the small intestine). |
| Onset of Action | Intravenous infusion: Immediate (within seconds to minutes) effect on serum potassium levels; clinical effect on cardiac conduction (ECG changes) seen within minutes. Oral: onset of action is delayed (1-2 hours) for absorption and redistribution. |
| Duration of Action | Intravenous: Duration depends on rate of infusion and renal elimination; effect lasts as long as infusion continues. After cessation, serum potassium returns to baseline within hours. Oral: duration of effect is 4-6 hours for maintenance therapy; sustained-release formulations extend duration. |
| Molecular Weight | Potassium chloride: 74.55 Da; Sodium chloride: 58.44 Da |
Intravenous infusion: Typically 10-20 mEq/h (max 40 mEq/h) with continuous ECG monitoring; rate not to exceed 1 mEq/min. Concentration: 0.15% KCl in 0.45% NaCl provides 2 mEq KCl per 100 mL. Administer via central line if concentration > 0.1%.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: No adjustment. GFR 30-50 mL/min: Reduce dose by 25% and monitor potassium closely. GFR < 30 mL/min: Avoid use unless severe hypokalemia and dialysis available; use with extreme caution, reduce dose by 50% and monitor ECG/serum K+ frequently. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce initial dose by 25% and titrate based on potassium levels. Child-Pugh C: Avoid use if possible; if necessary, reduce dose by 50% and monitor potassium and ECG closely due to risk of hyperkalemia. |
| Pediatric use | Intravenous infusion: 0.5-1 mEq/kg/dose, max 40 mEq/dose; rate not to exceed 0.5-1 mEq/kg/h under continuous ECG monitoring. Use with 0.45% sodium chloride; maximum infusion rate 0.5 mEq/kg/h. |
| Geriatric use | Start at lower end of dosing range (e.g., 5-10 mEq/h) due to age-related decline in renal function and increased risk of hyperkalemia. Monitor serum potassium and renal function frequently. Avoid rapid infusion rates. |
| 1st trimester | Potassium chloride and sodium chloride are normal physiological constituents; used for fluid and electrolyte replacement. No known teratogenic effects at therapeutic doses. Use only if clearly needed. |
| 2nd trimester | No known fetal risk. Monitor serum electrolytes to avoid hyperkalemia or hypernatremia. |
| 3rd trimester | Use with caution; excessive potassium may cause maternal hyperkalemia and fetal bradycardia. Avoid in preeclampsia or concurrent potassium-sparing diuretics. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium and chloride ions readily cross the placenta via active transport and diffusion; fetal serum levels are similar to maternal. No significant accumulation. |
| Breastfeeding | Both potassium and chloride are normal components of breast milk. No known adverse effects from maternal administration at therapeutic doses. Monitor infant for electrolyte disturbances if high doses used. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride and sodium chloride are physiological ions; no teratogenic risk is expected at therapeutic doses. Trimester-specific risks: no known fetal harm from electrolyte replacement. |
| Fetal Monitoring | Monitor serum electrolytes (potassium, sodium), renal function, fluid balance, and ECG in high-dose or rapid infusion. Assess maternal hydration status and fetal heart rate if maternal electrolyte disturbances occur. |
| Fertility Effects | No known effects on fertility with physiological electrolyte replacement. |
■ FDA Black Box Warning
None.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguriaAnuriaConcurrent use of potassium-sparing diureticsCholera-like diarrheaAddison's diseaseMetabolic alkalosis
| Precautions | Monitor serum potassium levels frequently to avoid hyperkalemia, Risk of hyperkalemia in patients with renal impairment, diabetes, or conditions causing tissue breakdown, Use with caution in patients with cardiac disease or receiving digitalis, Rate of infusion should not exceed 10 mEq/hour; concentration should not exceed 40 mEq/L |
| Food/Dietary | No significant food interactions. However, patients should avoid excessive dietary potassium intake (e.g., bananas, oranges, potatoes) while receiving this therapy, especially if renal function is compromised. |
| Clinical Pearls | This solution is used for maintenance fluid therapy when both potassium and sodium depletion are present. Monitor serum potassium and renal function; avoid use in severe renal impairment or hyperkalemia. Rapid infusion can cause hyperkalemia, especially in patients with impaired renal function or those on potassium-sparing diuretics. |
| Patient Advice | This intravenous solution contains potassium and sodium to replace electrolytes. · Inform your healthcare provider if you have kidney problems, heart disease, or are taking potassium supplements or diuretics. · Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations. · This medication will be given by a healthcare professional; do not attempt to adjust the infusion rate. |
Loading safety data…